<DOC>
	<DOCNO>NCT01500343</DOCNO>
	<brief_summary>The purpose study evaluate feasibility , safety effect inflammatory response therapy probiotic agent , yeast Saccharomyces boulardii ( SB ) , chronic heart failure patient .</brief_summary>
	<brief_title>A Pilot Study Probiotic Saccharomyces Boulardii Use Chronic Heart Failure Patients . Estudo PROICA</brief_title>
	<detailed_description>A cardiointestinal syndrome describe heart failure patient , morphologic functional intestinal disorder , increase enteropathogenic bacteria concentration , bacterial translocation inflammatory activation , thus contribute clinical worsen progression disease . In clinical practice , probiotic use several different condition , inflammatory bowel disease , acute antibiotic-associated diarrhea , food allergy , cancer , show benefit inflammation reduce bacterial translocation . However , use probiotic heart failure never describe .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Class I II ( NYHA ) heart failure patient Corticosteroid use within 30 day NSAID use within 30 day Antibiotic use within 30 day Acute infection Inflammatory diseases Autoimmune diseases Cancer Intestinal diseases Chronic renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>heart failure</keyword>
	<keyword>probiotic</keyword>
	<keyword>Saccharomyces boulardii</keyword>
	<keyword>cardio-intestinal syndrome</keyword>
	<keyword>gut</keyword>
	<keyword>inflammation</keyword>
</DOC>